Psoriasis is a chronic, systemic inflammatory disease that in the moderate to severe forms may benefit of biologics, namely TNF and IL-12/23 and IL-17 inhibitors. Loss of response, lack of response, or discontinuation due to adverse events represent a concrete therapeutic challenge for dermatologists that have to switch patients to other treatments. Although some evidences already exist toward the switch from IL-12/23 and TNF inhibitors to IL-17 inhibitors, conversely nothing is present toward the switch from IL-17 inhibitors to IL-12/23 and TNF inhibitors. We performed a real-life study enrolling 50 patients randomly switched to adalimuamb, a TNF inhibitor, or ustekinumab, an IL-12/23 inhibitor. Our observational study suggests that switching from IL-17i to TNFi and IL-12/23i is a safe and effective therapeutic strategy.
| INTRODUCTION
Psoriasis is a chronic, systemic inflammatory disease affecting 0.5-11.4% of the population (Michalek, Loring, & John, 2017 ). An increasing body of evidences seem to suggest that psoriasis-related comorbidities contributes to make challenging the choice of a systemic treatment, in particular dermatologists first should carefully screen relative and absolute contraindications Fiore, Leone, Maraolo, et al., 2018; Santus et al., 2018; Strober et al., 2018) . Furthermore, dermatologists are currently driven by experience and contraindication in choosing a biological therapy because of the lack of information of the so called biological signature of the patients (Feldman, Burudpakdee, Gala, Nanavaty, & Mallya, 2014) . About 25% psoriatic patients present moderate-to-severe psoriasis and deserve a biologic treatment, that actually includes IL17inhibitors(i) such as secukinumab, TNFi such as adalimumab and IL12/23i such as ustekinumab (Strober et al., 2018) . Due to the novelty of IL-17i, scattering evidences exists toward the switch between different IL-17i and from TNFi to IL-17i (Georgakopoulos, Ighani, Phung, & Yeung, 2018) . Conversely, no evidence for switching from IL-17i to TNFi or to anti-IL12/23i. To this end, we aimed to describe real-life characteristics of patients switching from secukinumab to adalimumab or ustekinumab.
| RESULTS
The enrolled cohort comprehended 50 patients, namely 28 males and 22 females with an average age of 43 AE 12.4 years old and average disease duration of 18.7 AE 8.6 years. Average BMI was 27.3 AE 2.1.
Prior to starting secukinumab, 34 patients were biologic naïve, In the adalimumab group at baseline, PASI was 15.5 AE 3.3 and DLQI was 16 AE 2.7 for patients who were biologic naïve prior to secukinumab (n = 23), 11 AE 4.0 and 22 AE 3, respectively for those receiving TNFi previously (n = 4) and PASI 15.5 AE 2.12 and DLQI 21.5 AE 2.1 for those on ustekinumab previously (n = 2). At week 28 all the four patients, that underwent TNFi before failing secukinumab, lost response to adalimumab and were switched to ixekizumab (n = 1) or ustekinumab (n = 3). At week 52, PASI was 2.8 AE 0.9 and DLQI 6 AE 2.3 for biologic naïve patients prior to secukinumab, and 3.1 AE 0.4 and 8 AE 1.2 respectively for those who received ustekinumab prior to starting secukinumab.
In the ustekinumab group at baseline, PASI was 18.5 AE 3.6 and DLQI was 14.3 AE 2 for patients who were biologic naïve prior to secukinumab (n = 11), 16 AE 2.4 and 22 AE 3.2 respectively for those receiving TNFi previously (n = 10). At week 52, PASI was 2.6 AE 0.3 and DLQI 4.1 AE 3.7 for biologic naïve patients prior to secukinumab, and 3.8 AE 0.2 and 10 AE 2.1, respectively for those who received TNFi prior to starting secukinumab.
One nonresponder in the biologic naïve prior to secukinumab group was switched to adalimumab, and the two nonresponders who previously received TNFi were switched to ixekizumab. No adverse events were recorded.
FIGURE 1 Therapeutic results for switching from secukinumab to adalimumab or ustekinumab Previously failed:
TNFi 4 10 14
• Adalimumab 0 8 8
• Etanercept 3 1 4
• Infliximab 1 1 2 IL-12/23i
• Ustekinumab 2 0 2 Naïve 23 11 34
• NB-UVB 10 9 19
• PUVA 1 2 3
• Cyclosporine 10 11 21
• Methotrexate 7 14 21
• Acitretin 4 1 4
Reasons to discontinue secukinumab
• Lack of efficacy at 16 weeks 12 13 15
• Loss of efficacy after 16 weeks 13 7 20
• Recurrent mucosal fungal infections 2 3 5
• Headache and hypertension 3 2 5
• Erysipelas 2 0 2
• Dizziness and nausea 1 1 2
• Hypertrigliceridemia 0 1 1 Secukinumab duration (months; mean AE SD) 45.8 AE 13.6 55.4 AE 3.7 49.6 AE 8.9
Comorbidities
• Hypertension (N) 2 2 4
• Psoriatic arthritis (N) 2 1 3
• Diabetes mellitus (N) 1 1 2
• Emphysema (N) 0 1 1 Nowadays, biologic drugs represent the standard treatment for moderate to severe psoriasis due to the high efficacy and promising safety (Georgakopoulos et al., 2018) . These drugs are particularly effective in patients who do not respond to conventional treatments. Despite these advantages, 10-30% of patients treated with TNFi or IL12/23i agents are still partial or nonresponders, or experience adverse effects, thus leading to treatment discontinuation (Umezawa et al., 2013; Warren, Smith, Yiu, et al., 2015) .
Therefore, these patients often switch to other biologics (Hu, Chen, Gong, & Shi, 2018) . The development of IL-17i agents has been met with great anticipation, and PASI 90 or even PASI 100 has been regarded as the new gold standard for satisfactory treatment response (Kerdel & Zaiac, 2015) . Physicians' high expectation of secukinumab efficacy, especially in patients with concurrent PsA, could lead to an earlier switching to well-established PsA-approved agents, such as adalimumab, in case these predictions are not met (Kerdel & Zaiac, 2015) . Furthermore, the high number of patients returning to their previous therapy upon failing on secukinumab could suggest that these were controlled with an acceptable but incomplete, skin clearance and consequently switched to secukinumab to obtain a lower PASI value (Piaserico, Cazzaniga, Chimenti, et al., 2014) . However, several studies have reported that patients previously treated with biologics display a lower PASI 75 than those treated with nonbiologics, suggesting that previously treated patients may fail on subsequent biologics as well (Fagerli et al., 2013; Georgakopoulos et al., 2018; Ritchlin, 2014) . While switching partial or nonresponding patients to a different biologic agent is a relatively common practice, few studies have assessed the efficacy of a second-line biologic treatment in these patients (Honda et al., 2017) . Therefore, we investigated these cases retrospectively by using patient records.
Our data indicate that patients nonresponders to secukinumab, where secukinumab was the first biologic drug underwent, may achieve significant improvements in PASI and DLQI by switching to adalimumab or ustekinumab. Furthermore, if the patient had received TNFi prior to secukinumab and subsequent secukinumab failure, the switching to ustekinumab is preferable than attempting another TNFi. 
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